Two clinical trials evaluating lisocabtagene maraleucel met their primary endpoints by demonstrating meaningful overall response rates among adults with follicular or mantle cell lymphomas, according to the agent’s manufacturer.
Lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb) — commonly called liso-cel — is a CD19-directed chimeric antigen receptor T-cell therapy.
The agent is approved in the United States for adults with relapsed or refractory large B-cell lymphoma who received two or more lines of systemic therapy. The agent also is approved for those whose disease